Cambridge biotech STORM Therapeutics raises $56 million

STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumor regression in multiple sarcoma subtypes. The $56 million Series C is fully backed by existing investors, including Pfizer Ventures and M Ventures. STORM…













